Clinical Trials

25 enrolled

Penile Squamous Cell Carcinoma (PSCC)

NCT04291885 2026-04-09

I-MAT

122 enrolled

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04841148 2026-04-09

PALAVY

96 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT04792073 2026-04-07

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

18 enrolled

Dermatologic

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT03573648 2026-03-19

ImmunoADAPT

33 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07460245 2026-03-10

AVESEC

144 enrolled

Carcinoma, Transitional Cell

NCT03006848 2026-02-23

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

19 enrolled 11 charts

Sarcoma

Osteosarcoma

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03944941 2026-02-05

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

60 enrolled

Dermatologic

Skin Neoplasms

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

9 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03744793 2026-01-09

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

18 enrolled

Carcinoma, Transitional Cell

NCT06518564 2026-01-07

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

25 enrolled

Gynecologic

Endometrial Neoplasms

NCT03391479 2025-12-18

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

25 enrolled

Neoplasm Metastasis, Penile Neoplasms

NCT04188119 2025-12-08

IMpALA

Phase 2 Withdrawn

Breast Neoplasms

NCT03747419 2025-10-31

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

14 enrolled 14 charts

Urinary Bladder Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

220 enrolled 11 charts

Breast Neoplasms

NCT04678362 2025-09-22

TALASUR

50 enrolled

Carcinoma, Transitional Cell

NCT04258956 2025-09-11

AXAGIST

58 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04341181 2025-07-25

ProTarget

300 enrolled

Neoplasms

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

106 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

100 enrolled 15 charts

Breast Neoplasms

NCT03186326 2025-06-29

SAMCO

132 enrolled

Colorectal Neoplasms

NCT03357757 2025-06-26

LATENT

39 enrolled

GastrointestinalLymphoid

Cancer That is Associated With a Chronic Viral Infection

NCT03971409 2025-05-02

InCITe

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

57 enrolled

Neoplasms, Second Primary

NCT06892860 2025-03-25

DISCUS

320 enrolled

Urinary Bladder Neoplasms

NCT06869473 2025-03-14

AVEC-119

67 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03674424 2025-02-26

AURA

137 enrolled

Non-metastatic Muscle Invasive Bladder Cancer

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT04562441 2025-01-10

NPC - AXEL Study : Axitinib-Avelumab

13 enrolled

Recurrence

NCT04513951 2025-01-09

AVETRIC

62 enrolled

Colorectal Neoplasms

NCT04068831 2024-12-27

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

18 enrolled 9 charts

Carcinoma, Renal Cell

NCT03278379 2024-12-24

NET-002

17 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT03990571 2024-10-18

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

40 enrolled 13 charts

Carcinoma, Adenoid Cystic, Disease Progression

NCT02875613 2024-08-28

Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

6 enrolled 8 charts

Head & Neck

Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT05574504 2024-08-01

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

Phase 2 Withdrawn

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03046953 2024-07-16

AVAIL-T

35 enrolled 21 charts

Lymphoid

Lymphoma

NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

8 enrolled 7 charts

Metastatic Castration-resistant Prostate Cancer

NCT03494322 2024-05-08

EACH

130 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05289856 2024-03-07

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

30 enrolled

Neoplasms

NCT03891238 2024-02-01

ARIES

67 enrolled

Neoplasm Metastasis

NCT05291156 2024-02-01

CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

173 enrolled

Colorectal Neoplasms

NCT03783936 2023-12-19

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

18 enrolled 16 charts

Adenocarcinoma Of Esophagus, Neoplasm Metastasis

NCT03617666 2023-12-12

AVENuE

49 enrolled

Lymphoid

Hodgkin Disease

NCT03503786 2023-11-13

MITO END-3

125 enrolled

Gynecologic

Endometrial Neoplasms

NCT03854799 2023-10-19

AVANA

101 enrolled

Colonic Neoplasms

NCT03390595 2023-10-18

INDUCOMAIN

85 enrolled

Carcinoma, Transitional Cell

NCT05600127 2023-09-08

CHASIT

64 enrolled

Carcinoma, Transitional Cell

NCT03568097 2023-06-02

PAVE